CRMP5 regulates cell proliferation and development of colorectal cancer via MAPK‑dependent signaling

Qiu,Fanghua; Yu,Lin; Liu,Daoli; Wu,Yujin; Qiu,Feng

doi:10.3892/ol.2021.13008

CRMP5 regulates cell proliferation and development of colorectal cancer via MAPK‑dependent signaling

Authors:
- Fanghua Qiu
- Lin Yu
- Daoli Liu
- Yujin Wu
- Feng Qiu
View Affiliations

Affiliations: Department of Infection Control, Guangzhou Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong 510130, P.R. China, Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, P.R. China, Department of Clinical Laboratory, Guangzhou Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong 510130, P.R. China, Department of Spleen and Gastroenterology, Guangzhou Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong 510130, P.R. China, Department of Laboratory Medicine, Nanhai Hospital, Southern Medical University, Foshan, Guangdong, 528244, P.R. China
Published online on: August 24, 2021 https://doi.org/10.3892/ol.2021.13008
Article Number: 747
Copyright: © Qiu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is one of the most common malignancies worldwide. Collapsin response mediator protein 5 (CRMP5) belongs to a family of five cytosolic proteins that serve a major role in neural development. CRMP5 has been identified as a biomarker of numerous cancer types, including lung cancer and glioblastoma. However, the role of CRMP5 in CRC remains unclear. In the present study, CRMP5 was characterized as a novel biomarker of poor survival in CRC. CRMP5‑overexpression in CRC cells promoted cell proliferation and migration while CPMP5‑knockdown decreased cell growth and migration. A novel mechanism was uncovered, by which CRMP5 regulates MAPK signaling to drive CRC cell proliferation and development. Furthermore, CRMP5‑overexpression induced chemotherapy resistance and tumor recurrence in CRC. Taken together, these results demonstrated the important role of CRMP5 in the development and proliferation of CRC cells and suggested that CRMP5 may be a novel therapeutic target for CRC.

View Figures

View References

1	El-Shami K, Oeffinger KC, Erb NL, Willis A, Bretsch JK, Pratt-Chapman ML, Cannady RS, Wong SL, Rose J, Barbour AL, et al: American cancer society colorectal cancer survivorship care guidelines. CA Cancer J Clin. 65:428–455. 2015. View Article : Google Scholar : PubMed/NCBI
2	Keum N and Giovannucci E: Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 16:713–732. 2019. View Article : Google Scholar : PubMed/NCBI
3	Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global patterns and trends in colorectal cancer incidence and mortality. Gut. 66:683–691. 2017. View Article : Google Scholar : PubMed/NCBI
4	Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387. 2018. View Article : Google Scholar : PubMed/NCBI
5	Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N and Honnorat J: Collapsin response mediator proteins (CRMPs): Involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol. 28:51–64. 2003. View Article : Google Scholar : PubMed/NCBI
6	Quach TT, Honnorat J, Kolattukudy PE, Khanna R and Duchemin AM: CRMPs: Critical molecules for neurite morphogenesis and neuropsychiatric diseases. Mol Psychiatry. 20:1037–1045. 2015. View Article : Google Scholar : PubMed/NCBI
7	Tan F, Thiele CJ and Li Z: Collapsin response mediator proteins: Potential diagnostic and prognostic biomarkers in cancers (Review). Oncol Lett. 7:1333–1340. 2014. View Article : Google Scholar : PubMed/NCBI
8	Gao X, Mao YH, Xiao C, Li K, Liu W, Li LY and Pang J: Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-kappaB/DNMT1 signaling pathway. Prostate. 78:682–690. 2018. View Article : Google Scholar : PubMed/NCBI
9	Moutal A, Honnorat J, Massoma P, Désormeaux P, Bertrand C, Malleval C, Watrin C, Chounlamountri N, Mayeur ME, Besançon R, et al: CRMP5 controls glioblastoma cell proliferation and survival through notch-dependent signaling. Cancer Res. 75:3519–3528. 2015. View Article : Google Scholar : PubMed/NCBI
10	Gozzard P, Woodhall M, Chapman C, Nibber A, Waters P, Vincent A, Lang B and Maddison P: Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study. Neurology. 85:235–239. 2015. View Article : Google Scholar : PubMed/NCBI
11	Veyrac A, Reibel S, Sacquet J, Mutin M, Camdessanche JP, Kolattukudy P, Honnorat J and Jourdan F: CRMP5 regulates generation and survival of newborn neurons in olfactory and hippocampal neurogenic areas of the adult mouse brain. PLoS One. 6:e237212011. View Article : Google Scholar : PubMed/NCBI
12	Ricard D, Rogemond V, Charrier E, Aguera M, Bagnard D, Belin MF, Thomasset N and Honnorat J: Isolation and expression pattern of human Unc-33-like phosphoprotein 6/collapsin response mediator protein 5 (Ulip6/CRMP5): Coexistence with Ulip2/CRMP2 in Sema3a- sensitive oligodendrocytes. J Neurosci. 21:7203–7214. 2001. View Article : Google Scholar : PubMed/NCBI
13	Meyronet D, Massoma P, Thivolet F, Chalabreysse L, Rogemond V, Schlama A, Honnorat J and Thomasset N: Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma. Am J Surg Pathol. 32:1699–1708. 2008. View Article : Google Scholar : PubMed/NCBI
14	Morrison DK: MAP kinase pathways. Cold Spring Harb Perspect Biol. 4:a0112542012. View Article : Google Scholar : PubMed/NCBI
15	Su B and Karin M: Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol. 8:402–411. 1996. View Article : Google Scholar : PubMed/NCBI
16	Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI
17	Burotto M, Chiou VL, Lee JM and Kohn EC: The MAPK pathway across different malignancies: A new perspective. Cancer. 120:3446–3456. 2014. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Lee JS: Exploring cancer genomic data from the cancer genome atlas project. BMB Rep. 49:607–611. 2016. View Article : Google Scholar : PubMed/NCBI
20	Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, et al: Recurrent R-spondin fusions in colon cancer. Nature. 488:660–4. 2012. View Article : Google Scholar : PubMed/NCBI
21	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404, 2012.22. View Article : Google Scholar : PubMed/NCBI
22	Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P and Vymetalkova V: 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther. 206:1074472019. View Article : Google Scholar : PubMed/NCBI
23	Hammond WA, Swaika A and Mody K: Pharmacologic resistance in colorectal cancer: A review. Ther Adv Med Oncol. 8:57–84. 2016. View Article : Google Scholar : PubMed/NCBI
24	Monstad SE, Nostbakken JK and Vedeler CA: CRMP5 antibodies found in a patient with limbic encephalitis and myasthenia gravis. J Neurol Neurosurg Psychiatry. 80:241–242. 2009. View Article : Google Scholar : PubMed/NCBI
25	Monstad SE, Drivsholm L, Skeie GO, Aarseth JH and Vedeler CA: CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunol Immunother. 57:227–232. 2008. View Article : Google Scholar : PubMed/NCBI
26	Wang L, Liu W, Tang H, Xie X, Zou C, Wang Y, Gao Z and Yin J: DRP5 is involved in cancer cell growth and predicts poor prognosis in human osteosarcoma. Cancer Med. 6:982–993. 2017. View Article : Google Scholar : PubMed/NCBI